Skip to main content

Table 1 Effect of ciprofibrate on the fasting plasma levels of lipids and glucose.

From: Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver

Mice groups

Triglycerides

(mg/dL)

Cholesterol

(mg/dL)

Free Fatty Acids

(mmol/L)

Glucose

(mg/dL)

Insulin

(ng/ml)

CIII

control

429 ± 134 (12)

124 ± 32 (12)

2.9 ± 0.5 (7)

70 ± 15 (6)

0.7 ± 0.2 (6)

 

treated

288 ± 140 (8)a

102 ± 39 (10)

2.2 ± 0.8 (10)

103 ± 24 (6)a

0.6 ± 0.2 (6)

CIII/CETP

control

320 ± 141 (10)

100 ± 23 (10)

3.5 ± 0.8 (10)

82 ± 23 (10)

0.7 ± 0.2 (9)

 

treated

226 ± 142 (9)

92 ± 20 (8)

2.4 ± 0.8 (8)

91 ± 20 (8)a

0.6 ± 0.3 (6)

CETP

control

86 ± 37 (10)

79 ± 27 (11)

1.7 ± 0.5 (12)

81 ± 27 (11)

0.6 ± 0.2 (8)

 

treated

49 ± 7 (9)b

78 ± 23 (11)

0.9 ± 0.3 (10)c

91 ± 23 (11)

0.5 ± 0.2 (12)

non-Tg

control

93 ± 38 (10)

74 ± 32 (10)

1.6 ± 0.6 (13)

69 ± 32 (10)

0.4 ± 0.2 (6)

 

treated

56 ± 12 (9)b

93 ± 25 (10)

1.3 ± 0.4 (8)

99 ± 27 (10)a

0.6 ± 0.2 (6)

  1. Normolipidemic (non-transgenic and CETP transgenic) and hypertriglyceridemic (CIII and CIII/CETP transgenic) mice were treated with ciprofibrate or vehicle (control) during 3 weeks. Mean ± SD (n). a p < 0.05; b p < 0.01; c p < 0.001 vs. control.